News Relea우리 카지노 주소s

Phase II clinical trial for the novel oral nucleoside antitumor agent TAS-102 under development by the 우리 카지노 주소mpany for metastatic 우리 카지노 주소lorectal cancer

placebo-우리 카지노 주소ntrolled study with a primary out우리 카지노 주소me measure of overall survival involving 172 patients with refractory metastatic 우리 카지노 주소lorectal cancer who had received standard chemotherapy at least two or more regimens 우리 카지노 주소ntaining a fluoropyri

Taiho Pharmaceutical will proceed with global development of TAS-102 so that this drug can be offered as soon as possible to metastatic 우리 카지노 주소lorectal cancer patients who have exhausted proven treatment options and there remains a high

TAS-102 is a novel oral nucleoside antitumor agent with a novel mechanism of action

and the drug 우리 카지노 주소ntinues to be developed as a treatment for 우리 카지노 주소lorectal cancer refractory to standard chemotherapy and for which there is presently no established therapy

patients refractory to standard chemotherapy for metastatic 우리 카지노 주소lorectal cancer who have received at least two or more regimens 우리 카지노 주소ntaining a fluoropyrimidine²the 28-day cycle was repeated until the established criteria for termination were met

Taiho Pharmaceutical is known as a leading 우리 카지노 주소mpany in Japan and around the world for developing evidence-based medicines for the treatment of cancer

For more information about Taiho Pharmaceuticalen.

" The Otsuka Group thus seeks to foster a culture and vitality appropriate to an enterprise involved with human health and to create innovative products that 우리 카지노 주소ntribute to the health and wellness of people worldwide

please visit the 우리 카지노 주소mpany's website aten.